Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis

Flohr, C. orcid.org/0000-0003-4884-6286, Irvine, A.D. orcid.org/0000-0002-9048-2044, Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (6 more authors) (2023) Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis. British Journal of Dermatology, 189 (2). pp. 238-240. ISSN 0007-0963

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Humans; Child; Dermatitis, Atopic; Quality of Life; Antibodies, Monoclonal, Humanized; Patient Reported Outcome Measures; Treatment Outcome; Severity of Illness Index; Double-Blind Method
Dates:
  • Accepted: 4 April 2023
  • Published (online): 30 April 2023
  • Published: August 2023
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Depositing User: Symplectic Sheffield
Date Deposited: 26 Jan 2024 11:08
Last Modified: 26 Jan 2024 11:08
Published Version: http://dx.doi.org/10.1093/bjd/ljad124
Status: Published
Publisher: Oxford University Press (OUP)
Refereed: Yes
Identification Number: https://doi.org/10.1093/bjd/ljad124
Related URLs:

Download

Export

Statistics


CORE (COnnecting REpositories)